Overall, co-administration preserves influenza immunogenicity but modestly reduces COVID-19 vaccine GMFR and the low absolute risk difference supports its feasibility as a strategy to streamline vaccination schedules and improve uptake.
Abstract
Seasonal influenza remains a leading cause of global morbidity and mortality, highlighting the need for vaccination strategies that improve coverage and streamline vaccine delivery. In this systematic review and meta-analysis, we searched PubMed, Embase, Web of Science, Scopus, and the Cochrane Central Register of Controlled Trials for randomised controlled trials (RCTs), cohort, case-control, and cross-sectional studies, evaluating immunogenicity and safety of same-day co-administration of influenza vaccines with COVID-19 or other vaccines, compared with non-concomitant administration. Comparators included sequential administration, single vaccine administration or placebo-controlled delayed vaccination. Risk of bias was evaluated using the Cochrane Risk-of-Bias tool for Randomized Trials and Risk of Bias In Non-randomized Studies of Interventions; certainty of evidence was evaluated using Grading of Recommendations, Assessment, Development and Evaluation. Immunogenicity was assessed using geometric mean fold rise (GMFR) in antibody titres and seroprotection rate. Safety was assessed by adverse event (AE) incidence. 52 eligible studies were included. Influenza immunogenicity was comparable between the co-administration and non-concomitant comparator group across all strains (H1N1 GMFR ratio of means (ROM): 1.02 [95% CI: 0.95–1.10]; H3N2, 1.05 [95% CI: 0.97–1.13]; B strain, 1.01 [95% CI: 0.97–1.05]). Pooled risk ratio (RR) for seroprotection was 1.00 for all three strains with 95% CIs ranging from 0.99–1.01. GMFR for COVID-19 vaccines was modestly reduced under co-administration (ROM 0.84 [95% CI: 0.74–0.95];
p
= 0.006). Serious AEs were more frequent in the co-administration group compared to the non-concomitant group (RR 1.41 [95% CI: 1.07–1.86];
p
= 0.014; absolute risk difference: 1.56 percentage points). Overall, co-administration preserves influenza immunogenicity but modestly reduces COVID-19 vaccine GMFR. Although safety findings warrant cautious interpretation, the low absolute risk difference supports its feasibility as a strategy to streamline vaccination schedules and improve uptake.
Dengue vaccines were generally well tolerated, with most adverse events being mild to moderate during follow-up, and future attempts should focus on developing Dengue vaccines that provide safe, balanced, and durable protection against all four Dengue virus serotypes while minimizing the risk of antibody-dependent enha...
D. Zaçe, A. Cekrezi, Martina Leone et al.· Le infezioni in medicina· 1 citation
LNP-encapsulated mRNA vaccines against RSV are safe and generate a good neutralising antibody response in adults, supporting their potential as an effective preventive strategy.
Farwa Saleem, Y. Tehreem, Ume Hani et al.· Journal of Saidu Medical Col...· 0 citations
ABSTRACT Individual studies indicate stronger and persistent long-term immunogenicity with TZ84-based than HM175-based hepatitis A vaccines. This systematic review and meta-analysis compared immunogenicity and safety of inactivated TZ84- and HM175-based hepatitis A vaccines in children and adolescents. Studies involvin...
R. Kundu, A. Ghosh, A. Toppo et al.· Human Vaccines & Immunothera...· 0 citations
The meta-analysis provides robust estimates for use in decision-analytical models designed to predict the impact of Hib vaccine, and provides robust estimates for use in decision-analytical models designed to predict the impact of Hib vaccine.
U. Griffiths, A. Clark, B. Gessner et al.· 0 citations
The exploratory synthesis did not show a clear difference between MF59-adjuvanted and high-dose vaccines, but sensitivity to outcome selection, heterogeneity estimation and potentially overlapping populations limits interpretation.
Daniela Amicizia, F. Marchini, I. Schenone et al.· Vaccines· 0 citations